GynoPharma's Paragard
This article was originally published in The Gray Sheet
Executive Summary
FDA approves labeling change extending use of the intrauterine copper contraceptive from eight to ten years, GynoPharma says, making Paragard "viable for twice as many years as any ether available reversible contraceptive." Other labeling changes include additional data on the risk of pelvic inflammatory disease associated with intrauterine devices